Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Home / IVDR Info

altona Diagnostics is aware that the European Commission has realeased a proposal in January 2024 affecting the Regulation (EU) 2017/745 to extend the transition periods of IVDD CE-marked products. We will update our website section “Approach to the IVDR” accordingly.

altona Diagnostics’ approach to the IVDR

Everything you need to know

The IVDR and altona Diagnostics
The IVDR is fully applicable since May 26, 2022. altona Diagnostics is ready.
Learn more


Amendment to the IVDR
Extended transition periods for products CE-marked under the IVDD have been accepted by the EU: IVDD products can be placed on the market until May 26 of 2025, 2026 and 2027, respectively, depending on the IVDR risk classification of the product.
Learn more


altona Diagnostics product portfolio and the IVDR
AltoStar® and FlexStar® products will be fully IVDR compliant and be available as IVD products for the foreseeable future.
Learn more


Extended availability of RealStar® products
Most RealStar® products will be offered as IVDD products until the respective transition period according to IVDR risk classes ends. RealStar® RUO products will remain available beyond these dates.
Learn more


Steps to IVDR compliance
At all times, customers will receive IVD products from altona Diagnostics, which are fully compliant with the applicable regulations.
Learn more


altona Diagnostics and the IVDR
Learn more

The IVDR and altona Diagnostics


Laboratories all over Europe are affected by immense regulatory changes applying to diagnostic devices and laboratory-developed tests (LDTs). The in vitro diagnostic regulation (IVDR), (EU) 2017/746) entered into force in 2017 and has superseded the in vitro diagnostic directive (IVDD, 98/79/EC) with full applicability since May 26, 2022. However, prolonged transition periods were established for IVDD products.

The new regulation will head the diagnostic market towards an increase in transparency, comparability, robust results, and reliability, respectively. The combination of these improvements will be beneficial to patients, clinicians, and laboratory professionals alike.


altona’s stance

Among the changes introduced by the IVDR are, for example, the increased involvement of notified bodies, a new risk classification system, and enhanced post-market surveillance and transparency. Therefore, altona Diagnostics has forcefully combined capacities for years to develop products corresponding to the IVDR. We are converting our AltoStar® and FlexStar® products into IVDR compliant versions.

Amendment to the IVDR

Extended transition periods

The diagnostic market faced major changes with the full applicability of the IVDR. In the advent of the tremendous shift, the European Commission composed a proposal to the IVDR in 2021. The suggestions were approved by the European Parliament and the EU Council. The proposal has led to an amendment to the IVDR, which provides updated transition periods.


Although the requirements of the IVDR remained unaffected, the following aspects apply with the publication of the Official Journal of the EU on January 28, 2022:

  • Full applicability of the IVDR by May 26, 2022
  • IVDR transition periods for IVDD products are extended according to the IVDR risk class
    • Future class D products benefit from a transition period placing IVDD products on the market until May 26, 2025 (e.g., highly pathogenic viruses, Lassa virus, Ebola virus, SARS-CoV-2, HIV, HBV, HCV)
    • Future class C products benefit from a transition period placing IVDD products on the market until May 26, 2026 (e.g., most other pathogens, herpes-/polyomaviruses, HAV, HEV, WNV, DENV, CHIKV, Plasmodium species)
    • Future class B products benefit from a transition period placing IVDD products on the market until May 26, 2027 (e.g., norovirus, rotavirus, non-pandemic influenza A/B virus, RSV, hMPV)
  • Future class A products will have to be IVDR compliant until May 26, 2022.


altona’s stance

As the consequences of the COVID-19 pandemic have intensively impacted all parts of the healthcare sector, altona Diagnostics perceives the transition periods of the amendment to the IVDR as positive, retaining both high-level quality and unrestricted availability of diagnostic products, e.g., PCR assay kits. Despite the extension of IVDR transition periods, altona Diagnostics has already taken action to convert our product portfolio to IVDR compliance.

altona Diagnostics product portfolio and the IVDR

Details 2023-2027 and beyond

altona Diagnostics is committed to provide IVDR-ready products to our customers to facilitate early adoption of the new requirements. We have focused on the approach of launching AltoStar® products, which comprise a technical documentation that is prepared to meet the requirements of the IVDR. These products combine the AltoStar® Molecular Diagnostic Workflow with the usability of other workflows (manual or automated) and, in this way, are “open workflow” compatible.


The AltoStar® product line is already available as CE-IVD and all upcoming products of the new FlexStar® product line will also be available as CE-IVD. These products are aimed to be IVDR compliant in 2024 certified by the notified body. Given that the IVDR has gained full applicability by May 26, 2022, our products of the risk class A are already IVDR compliant. This applies to the AltoStar® Purification Kit 1.5, the AltoStar® Whole Blood Pretreatment Buffer 1.5, and the FlexStar® (RT-)PCR Amplification Mix 1.5.

Following the IVDR amendment, RealStar® products will remain available as IVDD compliant CE-IVD products. Nevertheless, RealStar® products will not be released as an IVDR compliant version, in contrast to the AltoStar® and FlexStar® counterparts, but will be eventually discontinued. Hence, the last shipments of RealStar® CE-IVD products will be processed in line with the end of the applicable transition periods according to the respective IVDR risk class. altona Diagnostics kindly asks for your understanding that we are not yet able to provide a more precise discontinuation date for individual RealStar® CE-IVD products at this point. We will keep you posted and inform you about dates ahead of time. These dates will also be posted on this web page. However, RealStar® products will remain available as for research use only (RUO).

Overview 2023-2027 and beyond

Steps to IVDR compliance

The successful transition of marketed devices to IVDR compliance requires dedicated and enduring preparation. altona Diagnostics initiated the process early to obtain AltoStar® products which will be compliant with the IVDR and cover the needs of customers who are not yet benefiting from the automated AltoStar® Workflow. These CE-IVD products are available for orders.


However, to achieve full IVDR readiness altona Diagnostics must rely on a multiple-step model. The majority of in vitro diagnostic devices have to be approved by the notified body under the IVDR. Since the notified body supervising altona Diagnostics was IVDR certified, the technical documentation of selected products is reviewed before an IVDR audit can be performed. We will be allowed to get certified to declare product conformity under the IVDR. With the achievement of that milestone, altona Diagnostics will be capable to conduct the necessary activities to eventually transform the CE-IVD devices into IVDR compliant versions. Nevertheless, customers can already benefit from our products ahead of the implementation of the switch to achieve full IVDR compliance.

Frequently asked questions — IVDR and altona Diagnostics

When did the IVDR come into force?

The IVDR gained full applicability by May 26, 2022. Devices, which belong to the IVDR risk class A, must be IVDR compliant since then. IVD devices, which are categorized to future IVDR risk classes B–D, benefit from transition periods of 3 to 5 years.

What impact does the IVDR have on the altona Diagnostics portfolio?

altona Diagnostics is committed to conduct the transition from IVDD to IVDR products for customers smoothly and quickly. However, the IVD regulation has certain impacts on the product portfolio:

  • Products of the (automated) AltoStar® product line were relaunched in December 2021 comprising an “open workflow” usability. The products will become fully IVDR compliant in 2024 due to ongoing regulatory reasons.
  • Upcoming IVD products of the AltoStar® and FlexStar® product line will be launched meeting the requirements of the new IVD regulation.
  • CE-IVD products of the RealStar® product line will eventually be discontinued. However, the product line benefits from the extended transition periods for IVD devices. Within this period, we work on new products that will replace the current products. Additionally, we highly encourage the use of already IVDR compliant AltoStar® and FlexStar® products. Most RealStar® assays will be still available as RUO after the transition periods.

For more detailed information concerning our products please contact your local altona Diagnostics sales representative.

How long are the transition periods for the respective products?

The IVDR transition periods for IVDD products were extended according to the IVDR risk class.

  • Class A products must be IVDR compliant from May 26, 2022.
    This affects the following products*: the AltoStar® Purification Kit 1.5, the AltoStar® Whole Blood Pretreatment Buffer 1.5, the FlexStar® (RT-)PCR Amplification Mix 1.5, the ExtraStar® Purification Kit 2.0 and the AltoStar® Respiratory Sample Pretreatment Buffer 1.5.
  • Future class B products benefit from a transition period which allows the placing of IVDD products on the market until May 26, 2027.
    This will take effect on the products for norovirus, rotavirus, influenza A/B virus (non-pandemic), RSV, PIV, hMPV, C. difficile, and the AltoStar® Internal Control 1.5.
  • Future class C products benefit from a transition period which allows the placing of IVDD products on the market until May 26, 2026.
    This will take effect on the products for STIs or products with the specimen type blood or CSF such as CMV, EBV, BKV, JCV, HAdV, HHV 6, HSV, VZV, HAV, HEV, parvovirus B19, enterovirus, C. trachomatis, N. gonorrhoeae, Zika virus, WNV, DENV, CHIKV, Plasmodium sp., T. cruzi, B. pertussis, C./M. pneumoniae and Pneumocystis.
  • Future class D products benefit from a transition period which allows the placing of IVDD products on the market until May 26, 2025.
    This will take effect on the high-risk products for HIV, HBV, HCV, HDV, MERS-CoV, SARS-CoV-2, CCHFV, ebolavirus, Marburg virus, Lassa virus and yellow fever virus.

*IVDR-compliant products versions already available.

What are the differences between IVDD and IVDR?

The in vitro diagnostic directive (IVDD) was replaced by the in vitro diagnostic regulation (IVDR). This goes in line with the following major aspects:

  • Function (e.g., screening, monitoring, diagnosis) of the IVD needs to be described within the intended use
  • A new risk classification system categorizing the pathogens (many pathogens are ranked higher, leading to more elaborate requirements applying to the technical documentation)
  • Involvement of notified body becomes mandatory for most products (increased transparency and security for users of the IVDs)
  • New clinical evidence requirements (improvement of demonstrating the product performance)
  • Enhanced focus on post-market surveillance, vigilance, and the introduction of the EU database on medical devices (EUDAMED) to increase transparency

What is the impact of the IVDR on LDTs?

Laboratory developed tests (LDTs), which are in-house developed and produced by healthcare institutions, fall within the scope of the IVDR. LDTs must fulfill the General Safety and Performance Requirements of the Annex I of the IVD Regulation since May 26, 2022, and additionally, the marketing and transfer of LDTs to other legal entities are no longer permitted. Thus, laboratories do have to demonstrate compliance with the Annex I. Further requirements (such as QM system, EN ISO 15189 compliance (accreditation of laboratory), provision of information to the competent authority, declaration of the fulfillment of Annex I, compiling the technical documentation) have to be fulfilled starting May 26, 2024. In addition, the justification of the use of LDTs (e.g., proof of uniqueness of the LDT) will be mandatory starting May 26, 2028.


If an adequate product is available for the diagnosis/treatment of a (rare) disease, the usage of commercially available PCR assays over LDTs will be highly recommended. That recommendation is underlined by powerful arguments providing multiple major advantages such as:

  • Strict quality control of manufactured (raw-)materials and products
  • Intense post-market surveillance and post-market performance to identify any weaknesses and (e.g., changes in nucleic acid sequence of pathogens) early on
  • Reduced workload for laboratories in terms of establishing and maintaining the technical documentation

If laboratories still need to run LDTs (e.g., due to uniqueness of the LDT), altona Diagnostics can offer the FlexStar® LDT (RT-)PCR Detection Mix 1.5 RUO (see here for details) accompanied by the automation on the AltoStar® workflow to support consolidation on one workflow.

How is the classification of the risk classes under IVDR?

How are instruments impacted by the IVDR?

Instruments are also affected by the IVDR and must comply with the requirements of the regulation. However, instruments that were placed on the market as CE-IVDD may be used to the respective expiry date. This also applies to instruments for which no expiry date was assigned. Subsequent CE marking under the IVDR of products already in the market is not feasible, however, also not necessary